Phenotypes Associated with This Genotype

Genotype
MGI:6105947

• Allelic Composition: Tg(Myh6-Gnaq*Q209L/Esr1*)7Rzl/0
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:104100 )

• about 1/3 of tamoxifen-injected mice die within 28 days, although not all of these mice are edematous or ill

cardiovascular system

abnormal heart morphology ( J:104100 )

• interstitial space between myocytes is increased in hearts of tamoxifen treated mice, although only a minimal increase in interstitial fibrosis is seen

enlarged heart ( J:104100 )

• mice exhibit enlarged hearts after 28 days of tamoxifen treatment

increased heart weight ( J:104100 )

• mice exhibit a 1.89-fold increase in heart weight/tibial length ratio after 28 days of tamoxifen injection

dilated heart ventricle ( J:104100 )

• mice exhibit ventricular dilatation after 28 days of tamoxifen treatment

dilated cardiomyopathy ( J:104100 )

• in tamoxifen treated mice

• however, myocyte hypertrophy is not seen

decreased cardiac muscle contractility ( J:104100 )

• both maximum and minimum dP/dt values are altered after 7 days of tamoxifen treatment, indicating a contractile defect affecting both contraction and relaxation phase of the heart beat

abnormal cardiac muscle relaxation ( J:104100 )

• both maximum and minimum dP/dt values are altered after 7 days of tamoxifen treatment, indicating a contractile defect affecting both contraction and relaxation phase of the heart beat

abnormal heart echocardiography feature ( J:104100 )

• left ventricle end diastolic pressure is elevated 21-fold, and left ventricle end systolic presure and ejection fractions are depressed in tamoxifen treated mice

decreased heart rate ( J:104100 )

• heart rate is depressed in tamoxifen treated mice

abnormal myocardial fiber calcium currents ( J:104100 )

• tamoxifen-treated myocytes exhibit a decrease in L-type calcium current density

congestive heart failure ( J:104100 )

• mice progress into overt heart failure with continued tamoxifen treatment

growth/size/body

enlarged heart ( J:104100 )

• mice exhibit enlarged hearts after 28 days of tamoxifen treatment

increased heart weight ( J:104100 )

• mice exhibit a 1.89-fold increase in heart weight/tibial length ratio after 28 days of tamoxifen injection

weight loss ( J:104100 )

• tamoxifen treated mice that show a distended abdomen lose weight and develop a disheveled appearance and decreased mobility

increased body weight ( J:104100 )

• edematous mice show an average body weight increase of 33%

distended abdomen ( J:104100 )

• tamoxifen treated mice that do not develop severe peripheral edema exhibit a distended abdomen, suggesting presence of ascites

homeostasis/metabolism

edema ( J:104100 )

♂ • about 2/3 of male mice treated with tamoxifen at 8 weeks of age develop peripheral edema between 21 and 28 days of tamoxifen injection

integument

disheveled coat ( J:104100 )

• tamoxifen treated mice that show a distended abdomen lose weight and develop a disheveled appearance and decreased mobility

muscle

dilated cardiomyopathy ( J:104100 )

• in tamoxifen treated mice

• however, myocyte hypertrophy is not seen

decreased cardiac muscle contractility ( J:104100 )

• both maximum and minimum dP/dt values are altered after 7 days of tamoxifen treatment, indicating a contractile defect affecting both contraction and relaxation phase of the heart beat

abnormal cardiac muscle relaxation ( J:104100 )

• both maximum and minimum dP/dt values are altered after 7 days of tamoxifen treatment, indicating a contractile defect affecting both contraction and relaxation phase of the heart beat

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
congestive heart failure		DOID:6000		J:104100